Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Clinical trial NCT05260437 · COMPLETED
Trial details
- NCT number
- NCT05260437
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-24
- Primary completion
- 2023-03-07
- Enrollment
- 99
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.